WebCytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the … WebCYTK Cytokinetics Inc. Annual Income Statement - WSJ Subscribe Sign In Cytokinetics Inc. CYTK (U.S.: Nasdaq) View All companies AT CLOSE 4:00 PM EDT 03/28/23 $34.98 …
Did you know?
WebNov 3, 2024 · SOUTH SAN FRANCISCO, Calif., Nov. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2024. Net loss for the third quarter was $76.1 million, or $0.95 per share, compared to net loss for the third quarter of 2024 of $3.2 million, or $0.05 per share. WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated ( Nasdaq: CYTK) today announced that Robert I. Blum, …
WebCytokinetics Stock Is Surging. Heart-Drug Results Are Exciting Investors. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-4.25 Market Cap $3.46 B Shares Outstanding 95.16 … WebApr 13, 2024 · The projected fair value for Cytokinetics is US$38.04 based on 2 Stage Free Cash Flow to Equity. Cytokinetics' US$34.05 share price indicates it is trading at similar levels as its fair value estimate
WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2024. Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2024 was $389.0 million or $4.33 per share. WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 …
WebApr 10, 2024 · Zacks Equity Research. April 10, 2024, 9:23 AM · 3 min read. It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated …
WebAug 4, 2024 · SOUTH SAN FRANCISCO, Calif., Aug. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2024. Net loss for the second... lithium ion battery tariff codeWebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2024. Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2024 was $389.0 million or $4.33 per share. impurity\\u0027s grWebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, … impurity\\u0027s gsWeb2 days ago · Cytokinetics, Incorporated (CYTK) 45.71 +1.58 (3.58%) Feb 17, 2024, 4:00 PM EST - Market closed Overview Financials Statistics Forecast Dividends Profile Chart … impurity\u0027s goWebCYTK Cytokinetics Inc. Annual Income Statement - WSJ Subscribe Sign In Cytokinetics Inc. CYTK (U.S.: Nasdaq) View All companies AT CLOSE 4:00 PM EDT … impurity\\u0027s gqWebFind real-time CYTK - Cytokinetics Inc stock quotes, company profile, news and forecasts from CNN Business. ... Financials. Next reporting date: May 11, 2024: EPS forecast (this quarter) lithium ion battery tenderWebFeb 6, 2014 · Financial Guidance 2014. Cytokinetics also announced its financial guidance for 2014. The company anticipates cash revenue will be in the range of $19 to $21 million, cash R&D expenses will be in ... lithium ion battery symbol